RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets
The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Cancer transcriptomes frequently exhibit RNA dysregulation. As the resulting aberrant transcripts may be translated into cancer-specific proteins, there is growing interest in exploiting RNA dysregulation as a source of tumor antigens (TAs) and thus novel immunotherapy targets. Recent advances in high-throughput technologies and rapid accumulation of multiomic cancer profiling data in public repositories have provided opportunities to systematically characterize RNA dysregulation in cancer and identify antigen targets for immunotherapy. However, given the complexity of cancer transcriptomes and proteomes, important conceptual and technological challenges exist. Here, we highlight the expanding repertoire of TAs arising from RNA dysregulation and introduce multiomic and big data strategies for identifying optimal immunotherapy targets. We discuss extant barriers for translating these targets into effective therapies as well as the implications for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A total of 8.19% of TP53 mutant tumors were detected to carry nonsense mutations and were cleared by the nonsense-mediated mRNA decay (NMD) machinery during transcription555,556 (Fig. 1a).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [556]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The biogenesis, biology and characterization of circular RNAs
Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., & Kjems, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0158-7 · Cited by 4,823 · cited 2×
“Circular RNAs (circRNAs) are a unique class of RNA molecules with a covalently closed loop, formed by back-splicing events during pre-mRNA splicing (Figure 2) [35].”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationOpportunities and challenges in long-read sequencing data analysis
Amarasinghe, S. L., Su, S., Dong, X., Zappia, L., Ritchie, M. E., & Gouil, Q. (2020) · Genome Biology · doi:10.1186/s13059-020-1935-5 · Cited by 2,530 · cited 4×
“Despite its potential, long-read RNA-seq remains an under-used technology for human transcriptome analysis due to its high error rate and low throughput, along with the associated computational challenges [60].”
BackgroundMethodInfluentialAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Mass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334 · cited 1×
“MS-based proteomics characterizes protein expression and modifications at a global scale [70].”
BackgroundRegev, A., Teichmann, S. A., Lander, E. S., Amit, I., Benoist, C., Birney, E., Bodenmiller, B., Campbell, P., Carninci, P., Clatworthy, M., et al. (2017) · eLife · doi:10.7554/elife.27041 · Cited by 2,232
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
RNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915
Extensive translation of circular RNAs driven by N6-methyladenosine
Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L.-L., Wang, Y., et al. (2017) · Cell Research · doi:10.1038/cr.2017.31 · Cited by 1,855
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820
Pamudurti, N. R., Bartok, O., Jens, M., Ashwal-Fluss, R., Stottmeister, C., Ruhe, L., Hanan, M., Wyler, E., Perez-Hernandez, D., Ramberger, E., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.021 · Cited by 1,810
The Landscape of Circular RNA in Cancer
Vo, J. N., Cieslik, M., Zhang, Y., Shukla, S., Xiao, L., Zhang, Y., Wu, Y.-M., Dhanasekaran, S. M., Engelke, C. G., Cao, X., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.021 · Cited by 1,738
Regulatory activities of transposable elements: from conflicts to benefits
Chuong, E. B., Elde, N. C., & Feschotte, C. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.139 · Cited by 1,489
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.086 · Cited by 1,259
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
A-to-I editing of coding and non-coding RNAs by ADARs
Nishikura, K. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.4 · Cited by 1,041
Interpretation of Shotgun Proteomic Data
Nesvizhskii, A. I., & Aebersold, R. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r500012-mcp200 · Cited by 1,025
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Caesar-Johnson, S. J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 897
Self-citationToxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F., & Dietz, H. C. (2004) · Nature Genetics · doi:10.1038/ng1429 · Cited by 876
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Ellrott, K., Bailey, M. H., Saksena, G., Covington, K. R., Kandoth, C., Stewart, C., Hess, J., Ma, S., Chiotti, K. E., McLellan, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.002 · Cited by 852
Self-citationProteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance
Li, J., Sun, D., Pu, W., Wang, J., & Peng, Y. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.012 · Cited by 790
Proteogenomics: concepts, applications and computational strategies
Nesvizhskii, A. I. (2014) · Nature Methods · doi:10.1038/nmeth.3144 · Cited by 770
RNA processing and its regulation: global insights into biological networks
Licatalosi, D. D., & Darnell, R. B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2673 · Cited by 763
Hallmarks of alternative splicing in cancer
Oltean, S., & Bates, D. O. (2014) · Oncogene · doi:10.1038/onc.2013.533 · Cited by 664
Haas, B. J., Dobin, A., Li, B., Stransky, N., Pochet, N., & Regev, A. (2019) · Genome biology · doi:10.1186/s13059-019-1842-9 · Cited by 646 · cited 3×
“Certain types of cancer-associated transcripts, such as chimeric RNAs and expressed TEs, are particularly challenging to characterize by short-read RNA-seq [34, 56].”
BackgroundRibosome profiling: new views of translation, from single codons to genome scale
Ingolia, N. T. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3645 · Cited by 632
A-to-I RNA editing — immune protector and transcriptome diversifier
Eisenberg, E., & Levanon, E. Y. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0006-1 · Cited by 624
Transposable elements in cancer
Burns, K. H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.35 · Cited by 572 · cited 2×
“Dysregulation of TEs due to global loss of DNA methylation is common in human cancers (Figure 2) [51].”
BackgroundRozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.053 · Cited by 564
The rules and impact of nonsense-mediated mRNA decay in human cancers
Lindeboom, R. G. H., Supek, F., & Lehner, B. (2016) · Nature Genetics · doi:10.1038/ng.3664 · Cited by 545
Widespread and Functional RNA Circularization in Localized Prostate Cancer
Chen, S., Huang, V., Xu, X., Livingstone, J., Soares, F., Jeon, J., Zeng, Y., Hua, J. T., Petricca, J., Guo, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.025 · Cited by 544 · cited 1×
“CircRNAs perform biological functions in normal cells but can be dysregulated in cancer cells, resulting in distinct circRNA expression profiles in tumor tissues [36, 37].”
BackgroundSelf-citationThe Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H. M. J., Eterovic, A. K., Yuan, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.013 · Cited by 542 · cited 2×
“A-to-I RNA-editing is associated with clinically relevant features, including patient survival [45, 46], drug sensitivity [45], and cancer progression [47].”
BackgroundRibosome profiling reveals the what, when, where and how of protein synthesis
Brar, G. A., & Weissman, J. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4069 · Cited by 536
Noncoding regions are the main source of targetable tumor-specific antigens
Laumont, C. M., Vincent, K., Hesnard, L., Audemard, É., Bonneil, É., Laverdure, J.-P., Gendron, P., Courcelles, M., Hardy, M.-P., Côté, C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5516 · Cited by 535
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma
Chen, L., Li, Y., Lin, C. H., Chan, T. H. M., Chow, R. K. K., Song, Y., Liu, M., Yuan, Y.-F., Fu, L., Kong, K. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3043 · Cited by 517
Sarkizova, S., Klaeger, S., Le, P. M., Li, L. W., Oliveira, G., Keshishian, H., Hartigan, C. R., Zhang, W., Braun, D. A., Ligon, K. L., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0322-9 · Cited by 499
Proteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Measuring and interpreting transposable element expression
Lanciano, S., & Cristofari, G. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0251-y · Cited by 401
Genomic basis for RNA alterations in cancer
PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Demircioğlu, D., Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1970-0 · Cited by 393
Transposable elements drive widespread expression of oncogenes in human cancers
Jang, H. S., Shah, N. M., Du, A. Y., Dailey, Z. Z., Pehrsson, E. C., Godoy, P. M., Zhang, D., Li, D., Xing, X., Kim, S., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0373-3 · Cited by 392
The Expanding Landscape of Alternative Splicing Variation in Human Populations
Park, E., Pan, Z., Zhang, Z., Lin, L., & Xing, Y. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.11.002 · Cited by 360
Self-citationAlternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 351
Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells
Gupta, I., Collier, P. G., Haase, B., Mahfouz, A., Joglekar, A., Floyd, T., Koopmans, F., Barres, B., Smit, A. B., Sloan, S. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4259 · Cited by 343
Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors
Paz-Yaacov, N., Bazak, L., Buchumenski, I., Porath, H. T., Danan-Gotthold, M., Knisbacher, B. A., Eisenberg, E., & Levanon, E. Y. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.080 · Cited by 341
Intron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy
Lindeboom, R. G. H., Vermeulen, M., Lehner, B., & Supek, F. (2019) · Nature Genetics · doi:10.1038/s41588-019-0517-5 · Cited by 327
Intron retention is a source of neoepitopes in cancer
Smart, A. C., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D., Fugmann, T., Wong, K.-K., & Van Allen, E. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4239 · Cited by 322
Lessons from non-canonical splicing
Sibley, C. R., Blazquez, L., & Ule, J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.46 · Cited by 316
Predicting HLA class II antigen presentation through integrated deep learning
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., Muftuoglu, Y., Sworder, B. J., Diehn, M., Levy, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0280-2 · Cited by 314
Beyond mass spectrometry, the next step in proteomics
Timp, W., & Timp, G. (2020) · Science Advances · doi:10.1126/sciadv.aax8978 · Cited by 302
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285 · cited 3×
“Combining RNA-seq analysis with downstream analytical tools for protein inference and antigen prediction, researchers can detect candidate TAs derived from multiple types of RNA dysregulation [21, 23, 49, 54, 55].”
BackgroundMethodCancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Laumont, C. M., Daouda, T., Laverdure, J.-P., Bonneil, É., Caron-Lizotte, O., Hardy, M.-P., Granados, D. P., Durette, C., Lemieux, S., Thibault, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms10238 · Cited by 269
Alternative mRNA splicing in cancer immunotherapy
Frankiw, L., Baltimore, D., & Li, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0195-7 · Cited by 248
Roadblocks and resolutions in eukaryotic translation
Schuller, A. P., & Green, R. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0011-4 · Cited by 247
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 239
Self-citationRewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs
Walkley, C. R., & Li, J. B. (2017) · Genome Biology · doi:10.1186/s13059-017-1347-3 · Cited by 235
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Peng, X., Xu, X., Wang, Y., Hawke, D. H., Yu, S., Han, L., Zhou, Z., Mojumdar, K., Jeong, K. J., Labrie, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.026 · Cited by 223
Bosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., Rathi, K. S., Kendsersky, N. M., Randall, M., Donovan, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.003 · Cited by 215
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 214
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*
Caron, E., Kowalewski, D., Chiek Koh, C., Sturm, T., Schuster, H., & Aebersold, R. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.052431 · Cited by 213
Recurrent chimeric fusion RNAs in non-cancer tissues and cells
Babiceanu, M., Qin, F., Xie, Z., Jia, Y., Lopez, K., Janus, N., Facemire, L., Kumar, S., Pang, Y., Qi, Y., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw032 · Cited by 209
Apcher, S., Daskalogianni, C., Lejeune, F., Manoury, B., Imhoos, G., Heslop, L., & Fåhraeus, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104104108 · Cited by 169
Genome-wide identification and differential analysis of translational initiation
Zhang, P., He, D., Xu, Y., Hou, J., Pan, B.-F., Wang, Y., Liu, T., Davis, C. M., Ehli, E. A., Tan, L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01981-8 · Cited by 155
Nonsense-mediated mRNA Decay and Cancer
Popp, M. W., & Maquat, L. E. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.007 · Cited by 155
Single-cell RNAseq for the study of isoforms—how is that possible?
Arzalluz-Luque, Á., & Conesa, A. (2018) · Genome biology · doi:10.1186/s13059-018-1496-z · Cited by 154
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 152
RNA editing derived epitopes function as cancer antigens to elicit immune responses
Zhang, M., Fritsche, J., Roszik, J., Williams, L. J., Peng, X., Chiu, Y., Tsou, C.-C., Hoffgaard, F., Goldfinger, V., Schoor, O., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06405-9 · Cited by 151
Methods, Tools and Current Perspectives in Proteogenomics
Ruggles, K. V., Krug, K., Wang, X., Clauser, K. R., Wang, J., Payne, S. H., Fenyö, D., Zhang, B., & Mani, D. R. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.mr117.000024 · Cited by 148
Lee, J. K., Bangayan, N. J., Chai, T., Smith, B. A., Pariva, T. E., Yun, S., Vashisht, A., Zhang, Q., Park, J. W., Corey, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802354115 · Cited by 147
Self-citationThe problem with neoantigen prediction
(2017) · Nature Biotechnology · doi:10.1038/nbt.3800 · Cited by 145
Altered RNA Processing in Cancer Pathogenesis and Therapy
Obeng, E. A., Stewart, C., & Abdel-Wahab, O. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0399 · Cited by 139
Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis
Wen, B., Li, K., Zhang, Y., & Zhang, B. (2020) · Nature Communications · doi:10.1038/s41467-020-15456-w · Cited by 138
Shao, W., Pedrioli, P. G. A., Wolski, W., Scurtescu, C., Schmid, E., Vizcaíno, J. A., Courcelles, M., Schuster, H., Kowalewski, D., Marino, F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx664 · Cited by 135
Deep-learning augmented RNA-seq analysis of transcript splicing
Zhang, Z., Pan, Z., Yi, Y., Xie, Z., Adhikari, S., Phillips, J., Carstens, R. P., Black, D. L., Wu, Y., & Xing, Y. (2019) · Nature Methods · doi:10.1038/s41592-019-0351-9 · Cited by 115
Self-citationIntergenically Spliced Chimeric RNAs in Cancer
Jia, Y., Xie, Z., & Li, H. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.006 · Cited by 115
Wu, C.-S., Yu, C., Chuang, C.-Y., Hsiao, M., Kao, C.-F., Kuo, H., & Chuang, T. (2013) · Genome Research · doi:10.1101/gr.159483.113 · Cited by 108
Oka, M., Xu, L., Suzuki, T., Yoshikawa, T., Sakamoto, H., Uemura, H., Yoshizawa, A. C., Suzuki, Y., Nakatsura, T., Ishihama, Y., et al. (2021) · Genome Biology · doi:10.1186/s13059-020-02240-8 · Cited by 108
Cherry, S. R., & Lynch, K. W. (2020) · Genes & Development · doi:10.1101/gad.338962.120 · Cited by 95
The role of A-to-I RNA editing in cancer development
Xu, X., Wang, Y., & Liang, H. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.009 · Cited by 93
Quantification of translation uncovers the functions of the alternative transcriptome
Calviello, L., Hirsekorn, A., & Ohler, U. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0450-4 · Cited by 80
Phillips, J. W., Pan, Y., Tsai, B. L., Xie, Z., Demirdjian, L., Xiao, W., Yang, H. T., Zhang, Y., Lin, C. H., Cheng, D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915975117 · Cited by 76
Self-citationThe current revolution in transposable element biology enabled by long reads
Shahid, S., & Slotkin, R. K. (2020) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2019.12.012 · Cited by 66
Reixachs‐Solé, M., Ruiz‐Orera, J., Albà, M. M., & Eyras, E. (2020) · Nature Communications · doi:10.1038/s41467-020-15634-w · Cited by 59
Toward in silico Identification of Tumor Neoantigens in Immunotherapy
Zhou, C., Zhu, C., & Liu, Q. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.001 · Cited by 57
Research works printed but not linked: 2
- Ouspenskaia, 2020, Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer, bioRxiv
- Pan, 2019, IRIS: big data-informed discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing, bioRxiv
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Wang, Y., Xie, Z., Kutschera, E., Adams, J. I., Kadash-Edmondson, K. E., & Xing, Y. (2024) · Nature Protocols · doi:10.1038/s41596-023-00944-2 · Cited by 268
Self-citation
Metadata
- Authors
- Pan, Y., Kadash-Edmondson, K. E., Wang, R., Phillips, J., Liu, S., Ribas, A., Aplenc, R., Witte, O. N., & Xing, Y.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 42
- Issue
- 4
- Pages
- 268-282
- ISSN
- 0165-6147
- Cited by
- 53
- References
- 93
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institutes of Health
- National Cancer Institute (P50CA092131, R01CA220238, U01CA233074, U24CA232979)
- Parker Institute for Cancer Immunotherapy (20163828)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.